JHL Biotech Closes $35 Million Series B Financing - Siouxland News - KMEG 14 and FOX 44

JHL Biotech Closes $35 Million Series B Financing

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE JHL Biotech, Inc.

HSINCHU, Taiwan, June 19, 2014 /PRNewswire/ -- JHL Biotech, Inc., an emerging biopharmaceutical company, today announced that it has closed a Series B financing round of $35 million, led by new investors Milestone Capital and a consortium of Taiwan venture capitalists and individuals, including President International Development Corp., Fubon Financial Holdings, Taishin Financial Holdings, TaiAn Technologies, Hotung Group, Dr. Allen Chao (founder of Watson Pharmaceuticals), and existing Series A shareholders China Development Industrial Bank, Biomark Capital, and Kleiner Perkins Caufield & Byers. 

JHL will deploy the new funds toward developing its proprietary biosimilar monoclonal antibody pipeline and accelerating its filing of investigational new drug applications, whilst supporting the ongoing facility expansion in Taiwan and acquiring additional equipment for its commercial manufacturing facility in Wuhan, China, which is expected to be completed by 2014 year-end.

"Our investors recognize the hard work and progress we have made towards our mission of bringing affordable, quality medicines to Asia through our cross-strait presence in Taiwan and China," said Racho Jordanov, President and CEO of JHL Biotech.  "We are proud to be backed by these top-tier investors, both original and new, and look forward to continuing our work together to develop, manufacture, and commercialize world-class medicines."

JHL completed the construction of its clinical manufacturing facility in Hsinchu, Taiwan in December 2013 and has since formed partnerships with domestic academic and government institutions to discover new molecular entities, as well as with regional and global biotech and pharmaceutical companies to develop oncology and immunology drug candidates.

About JHL Biotech
JHL Biotech is an emerging biopharmaceuticals company founded in December 2012 by a group of biotech veterans and seeded by a consortium of top-tier venture capital firms that included Kleiner Perkins Caufield & Byers, Biomark Capital, China Development Industrial Bank, and Sequoia Capital, with the mission to develop, manufacture, and commercialize world-class, affordable biologic medicines.

JHL Biotech focuses on high-quality, cost-effective bioengineering as well as innovative product development technologies that follow current Good Manufacturing Practices (cGMP). In its first year, JHL Biotech has five biosimilar programs and one new molecular entity in development. JHL plans to submit its first clinical trial and investigational new drug applications in 2015.

For more information, please visit our website at www.jhlbiotech.com.

©2012 PR Newswire. All Rights Reserved.

  • NewsNewsMore>>

  • Congress Continues Failure to Compromise

    Congress Continues Failure to Compromise

    On capitol hill this week, a feeling of chaos once again. A familiar question: what has congress achieved since returning from its last recess? David Lublin is a professor in the Dept of Government at American University and says with both parties seemingly more unwilling than ever to compromise, politics trumped policy-making once again. "In some ways one wonders do they want it to be dysfunctional because then they can attack the dysfunctionality in the midterm elections to gain more seats...More >>
    On capitol hill this week, a feeling of chaos once again. A familiar question: what has congress achieved since returning from its last recess? David Lublin is a professor in the Dept of Government at American University and says with both parties seemingly more unwilling than ever to compromise, politics trumped policy-making once again. "In some ways one wonders do they want it to be dysfunctional because then they can attack the dysfunctionality in the midterm elections to gain more seats...More >>
  • IRS Scandal Investigation Heats Up

    IRS Scandal Investigation Heats Up

    The emails, from Lois Lerner's work issued blackberry to a friend, are about conservative talk show hosts and those who call into their shows.More >>
    (WASHINGTON, DC) The emails, from Lois Lerner's work issued blackberry to a friend, are about conservative talk show hosts and those who call into their shows.
    More >>
  • Will Ukraine Crisis Lead to New Cold War?

    Will Ukraine Crisis Lead to New Cold War?

    (WASHINGTON, D.C.) As the U.S. ratchets up economic sanctions against russia... some foreign policy experts suggest we are heading into a new "cold war."More >>
    (WASHINGTON, D.C.) As the U.S. ratchets up economic sanctions against russia... some foreign policy experts suggest we are heading into a new "cold war."
    More >>
Powered by WorldNow

Siouxland News
100 Gold Circle
Dakota Dunes, SD 57049

Main Phone: 712-277-3554
Main Fax: 712-255-5250
Email: webmaster@siouxlandnews.com

Powered by WorldNow
All content © Copyright 2000 - 2009 WorldNow and Sinclair Communications, LLC. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.